Samit Hirawat, Bristol Myers CMO
FDA OKs Bristol Myers Squibb’s LAG-3 drug, approving first new class of checkpoint inhibitor in 8 years
For the first time in nearly a decade, the FDA has approved a new type of checkpoint inhibitor to treat certain patients with cancer. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
